Over the last 4 years, insiders at Inari Medical have traded over $519,947,508 worth of Inari Medical stock and bought 1,100,480 units worth $22,863,324 . The most active insiders traders include Gilde Healthcare Iv U.A.Gil..., William Hoffman, and Andrew Hykes. On average, Inari Medical executives and independent directors trade stock every 7 days with the average trade being worth of $1,998,809. The most recent stock trade was executed by Andrew Hykes on 20 August 2024, trading 3,000 units of NARI stock currently worth $150,000.
Inari Medical, Inc., a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism. It also offers FlowSaver; FlowStasis, a large bore suture retention device designed to address various aspects of venous access site; and FlowTriever 2, a new disk shape designed to capture and remove wall adherent clot and shorten treatment. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.
Inari Medical executives and other stock owners filed with the SEC include: